eCFR Reference Browser

---

title: "21 CFR §520.1705"

source: "https://www.ecfr.gov/current/title-21/section-520.1705"

title_number: "21"

volume_number: "6"

chapter_number: "Unknown"

subchapter_code: "E"

subchapter_subject: "ANIMAL DRUGS, FEEDS, AND RELATED PRODUCTS"

part_code: "520"

part_subject: "ORAL DOSAGE FORM NEW ANIMAL DRUGS"

subpart_code: "B"

subpart_subject: "Specific Administrative Rulings and Decisions"

section_number: "520.1705"

section_subject: "Pergolide."

cfr_reference: "21 CFR 520.1705"

title_name: "Title 21"

title_subject: "Food and Drugs"

parts_covered: "Parts 500 to 599"

revised_date: "Revised as of April 1, 2019"

publication_date: "As of April 1, 2019"

contains_description: "Containing a codification of documents of general applicability and future effect"

publication_info: "Published by the Office of the Federal Register National Archives and Records Administration as a Special Edition of the Federal Register"

---

(a)Specifications. Each tablet contains 1 milligram (mg) peroglide (as pergolide mesylate).

(b)Sponsor. See No. 000010 in § 510.600(c) of this chapter.

(c)Conditions of use in horses—(1) Amount. Administer orally at a starting dose of 2 micrograms/kilograms (µ/kg) once daily. Dosage may be adjusted to effect, not to exceed 4 µg/kg daily.

(2)Indications for use. For the control of clinical signs associated with Pituitary Pars Intermedia Dysfunction (Equine Cushing's Disease).

(3)Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

§520.1705 - Pergolide.